Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

Publication | Open Access

DOI Full Paper Access

Citations

References

2020

Year

Josef S Smolen, Philip J. Mease, Hasan Tahir, Hendrik Schulze‐Koops, Inmaculada de la Torre, Lingnan Li, Maja Hojnik, Christophe Sapin, Masato Okada, Roberto Caporali,

Annals of the Rheumatic Diseases

Abstract

References